JPMorgan Chase & Co. Purchases Shares of 8,200 Palisade Bio, Inc. (NASDAQ:PALI)

JPMorgan Chase & Co. acquired a new position in shares of Palisade Bio, Inc. (NASDAQ:PALI) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 8,200 shares of the company’s stock, valued at approximately $29,000. JPMorgan Chase & Co. owned approximately 0.54% of Palisade Bio as of its most recent SEC filing.

Palisade Bio Stock Performance

Palisade Bio stock opened at $1.35 on Wednesday. Palisade Bio, Inc. has a fifty-two week low of $1.25 and a fifty-two week high of $9.65. The company has a market cap of $3.73 million, a PE ratio of -0.10 and a beta of 1.43. The business’s 50-day simple moving average is $1.78 and its two-hundred day simple moving average is $2.83.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter, topping the consensus estimate of ($3.35) by $1.03. As a group, analysts predict that Palisade Bio, Inc. will post -12.43 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PALI shares. Brookline Capital Management started coverage on Palisade Bio in a research report on Wednesday, November 20th. They set a “buy” rating and a $38.00 target price on the stock. Maxim Group dropped their target price on shares of Palisade Bio from $22.50 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.